Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m(2) versus 40 mg/m(2) in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial

OBJECTIVE: The standard dose for pegylated liposomal doxorubicin (PLD) is 50 mg/m(2) every 4 weeks. While 40 mg/m(2) has recently been used in clinical practice, evidence supporting this use remains lacking. METHODS: This phase III randomized, non-inferiority study compared progression-free survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Motohashi, Takashi, Yabuno, Akira, Michimae, Hiroshi, Ohishi, Tetsuro, Nonaka, Miwa, Takano, Masashi, Nishio, Shin, Fujiwara, Hiroyuki, Fujiwara, Keiichi, Kondo, Eiji, Sugiyama, Toru, Tabata, Tsutomu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767649/
https://www.ncbi.nlm.nih.gov/pubmed/33185050
http://dx.doi.org/10.3802/jgo.2021.32.e9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767649/
https://www.ncbi.nlm.nih.gov/pubmed/33185050
http://dx.doi.org/10.3802/jgo.2021.32.e9

Ejemplares similares